Yuhan Corporation Deal History & Licensing Activity
Yuhan Corporation is a large pharma headquartered in South Korea. The company currently has 17 active clinical trials, primarily in Solid Tumors.
Deals (12mo)
3
Active Trials
17
Top Modality
N/A
Focus Area
Solid Tumors
Yuhan Corporation Pipeline Focus
Therapeutic areas and modalities where Yuhan Corporation is most active based on deal history and clinical trial data.
Therapeutic Areas
Yuhan Corporation Strategic Signals
Key indicators of Yuhan Corporation's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Strategic Profile
Acquisition Appetite
Strategic Priorities
Yuhan Corporation Clinical Pipeline
Yuhan Corporation has 17 active clinical trials across 6 development phases.
1
Not Applicable
3
Phase 4
4
Unknown
5
Phase 1
2
Phase 2
2
Phase 3
See How Your Asset Matches Yuhan Corporation's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Solid Tumors assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Cardiovascular Deal Benchmarks
Market sizing, deal terms, and competitive landscape for cardiovascular
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Yuhan Corporation Licensing & Deal Activity
Yuhan Corporation is a large pharma company based in South Korea that has been actively engaged in licensing transactions across the biopharma landscape.
Key therapeutic areas of focus for Yuhan Corporation include Solid Tumors (4 deals and trials), Cardiovascular (3 deals and trials), Hematological Malignancies (2 deals and trials), and Metabolic (2 deals and trials).
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Yuhan Corporation and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against Yuhan Corporation's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.